ISLA-RT is an investigational peptide of the incretin class, supplied for laboratory research, with agonist activity across more than one incretin receptor.
The three receptors
The receptors concerned — GLP-1, GIP and glucagon — are all class B G-protein coupled receptors, and all three couple to Gs and raise cyclic AMP. Their tissue distribution is what separates them.
GLP-1 receptors appear on pancreatic beta cells and in the central nervous system, associated with glucose-dependent insulin secretion and appetite signalling. GIP receptors are found on beta cells and adipose tissue. Glucagon receptors are predominantly hepatic, associated with glucose output and energy expenditure.
Why combine agonism at three receptors
The glucagon receptor is the counterintuitive one. Glucagon raises blood glucose — apparently opposing the other two. The rationale in this class is that glucagon receptor agonism also increases energy expenditure and affects hepatic lipid handling, and that the glucose-raising effect can be offset by simultaneous GLP-1 and GIP activity.
So the pharmacology depends on the balance of potencies across the three receptors, not on any one of them. That balance is the defining property of any molecule in this class, and it is why two triple agonists are not interchangeable.
Research context
Multi-receptor incretin agonism is an active area of metabolic research. ISLA-RT is a house designation; identity and purity should be confirmed against the batch certificate of analysis rather than inferred from the product name.
Supplied lyophilised. See our reconstitution protocol for handling technique and diluent selection.
Every batch ships with a third-party certificate of analysis. View ISLA-RT and its current COA.
Research use only
Isla Longevity supplies this compound for laboratory research use only. It is not approved by the FDA for human or veterinary use and is not for human consumption. This article summarises published research and is not medical guidance.
